Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial

被引:20
作者
Reed, SD [1 ]
Friedman, JY
Gnanasakthy, A
Schulman, KA
机构
[1] Duke Univ, Med Ctr, Durham, NC 27706 USA
[2] Novartis Pharmaceut Corp, Basel, Switzerland
关键词
costs and cost analysis; hospital costs; health care costs; economics; pharmaceutical;
D O I
10.1017/S0266462303000357
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To develop and evaluate strategies for estimating hospitalization costs in multinational clinical trials. Methods: Hospital cost estimates for eleven diagnoses were collected from twelve countries participating in a trial of therapies for congestive heart failure. Estimates were combined with U.S.-based diagnosis-related group weights to compute country-specific unit cost estimates for all reasons for hospitalization. Variations of hospital costing methods were developed. The unit cost method assigns a country-specific unit cost estimate to each hospitalization. The other methods adjust for length of stay using a daily cost (DC) estimate for each diagnosis, based on either the mean length of stay (DC-mean method) or the median length of stay (DC-median method) for each diagnosis in each country. Additional modifications were explored through adjustment of the distribution of daily costs incurred during a hospital stay. Results: The mean cost for all hospitalizations was $10,242 (SID, 10,042) using the unit cost method, $10,242 (SD, 12,760) using the standard DC-mean method, and $13,967 (SD, 18,762) using the standard DC-median method. In comparisons of costs for all 5,486 hospitalizations incurred by a subset of 2,352 patients in the trial, the unit cost method provided 92% power to detect a $1,000 cost difference. The standard DC-mean method provided 76% power, and the standard DC-median method provided 44% power. Conclusions: Hospital costing methods that adjust for differences in length of stay require a significantly larger sample to attain comparable statistical power as methods that assign unadjusted unit cost estimates to hospitalization events.
引用
收藏
页码:396 / 406
页数:11
相关论文
共 18 条
[1]   A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure [J].
Cohn, JN ;
Tognoni, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1667-1675
[2]   Medicare's DRG-weights in a European environment: the Spanish experience [J].
Cots, F ;
Elvira, D ;
Castells, X ;
Dalmau, E .
HEALTH POLICY, 2000, 51 (01) :31-47
[3]   Economic evaluation of enoxaparin sodium versus heparin in unstable angina - A French sub-study of the ESSENCE trial [J].
Detournay, B ;
Huet, X ;
Fagnani, F ;
Montalescot, G .
PHARMACOECONOMICS, 2000, 18 (01) :83-93
[4]   An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer [J].
Groener, MGH ;
van Ineveld, BM ;
Byttebier, G ;
van Hout, BA ;
Rutten, FFH .
ANTI-CANCER DRUGS, 1999, 10 (03) :283-288
[5]   Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. [J].
Legendre, CM ;
Norman, DJ ;
Keating, MR ;
Maclaine, GDH ;
Grant, DM .
TRANSPLANTATION, 2000, 70 (10) :1463-1468
[6]  
Raikou M, 2000, HEALTH ECON, V9, P191, DOI 10.1002/(SICI)1099-1050(200004)9:3<191::AID-HEC510>3.0.CO
[7]  
2-1
[8]   Spending more through 'Cost control': Our obsessive quest to gut the hospital [J].
Reinhardt, UE .
HEALTH AFFAIRS, 1996, 15 (02) :145-154
[9]  
Rittenhouse BE, 1999, HEALTH ECON, V8, P213, DOI 10.1002/(SICI)1099-1050(199905)8:3<213::AID-HEC429>3.0.CO
[10]  
2-O